2015
DOI: 10.1097/mou.0000000000000180
|View full text |Cite
|
Sign up to set email alerts
|

The management of overactive bladder

Abstract: http://links.lww.com/COU/A7.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0
2

Year Published

2016
2016
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(8 citation statements)
references
References 26 publications
0
6
0
2
Order By: Relevance
“…In patients refractory to pharmacological treatment intravesical injection of botulinum toxin may be offered, although this requires frequent re-injection for continued benefit. There is also a risk of urinary tract infection and high residual volume, which may require patients to perform self-catheterization (Gupta et al, 2015 ; Tubaro et al, 2015 ; Olivera et al, 2016 ; Truzzi et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…In patients refractory to pharmacological treatment intravesical injection of botulinum toxin may be offered, although this requires frequent re-injection for continued benefit. There is also a risk of urinary tract infection and high residual volume, which may require patients to perform self-catheterization (Gupta et al, 2015 ; Tubaro et al, 2015 ; Olivera et al, 2016 ; Truzzi et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%
“…Percutaneous tibial nerve stimulation (PTNS) and sacral nerve stimulation (SNS) have both been adopted as clinical procedures for urge incontinence (Yamanishi et al, 2015 ). However, PTNS requires a frequent schedule of re-application whereas high levels of re-intervention are required with SNS and pain is a frequent side effect (Gupta et al, 2015 ; Tubaro et al, 2015 ; Olivera et al, 2016 ; Truzzi et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%
“…This therapy requires the injection of the toxin into the muscle of the bladder with the effects lasting from 6–8 months 18,19. Studies have shown that onabotulinum toxin A is highly effective in treating OAB symptoms, comparable to other third-line treatments 20. It is important to acknowledge that comparing these therapies is difficult because there is no clear-cut definition of clinical success or improvement and measuring each parameter is done differently for each study.…”
Section: Discussionmentioning
confidence: 99%
“…Uma revisão sistemática com artigos dos últimos 10 anos, comparando eletroestimulação sacral, NTP e toxina botulínica, demonstrou melhora na qualidade de vida (QV) por meio da eletroestimulação sacral. 17 O estudo não incluiu TMAP, mas afirmou que os resultados da última década mostram que as vantagens da eletroestimulação aumentaram muito em relação ao uso de medicamentos.…”
Section: Discussionunclassified